No Data
Further Weakness as Shenzhen Chipscreen Biosciences (SHSE:688321) Drops 5.8% This Week, Taking Five-year Losses to 64%
Shenzhen Chipscreen Biosciences (688321.SH): The sodium sijagliflozin tablet has received the notice of approval for the pharmaceutical supplementary application.
On December 6th, 2023, Gelonghui reported that shenzhen chipscreen biosciences (688321.SH) announced that it recently received a "Notice of Approval for Supplementary Application for Pharmaceuticals" issued by the National Medical Products Administration (Notice No.: 2024B05678). Siglepagliptin is a new mechanism insulin sensitizer independently developed by the company, classified as a national category 1 new drug and a significant achievement of the national "Major New Drug Creation" project. It was officially granted a "Drug Registration Certificate" by the National Medical Products Administration on October 19, 2021. So far, it has been approved in China for monotherapy for type 2 diabetes and in combination with metformin for type 2 diabetes.
Shenzhen chipscreen biosciences (688321.SH): The company's products have been included in the national medical insurance catalog.
GeLongHui November 28th | Shenzhen Chipscreen Biosciences (688321.SH) announced that on November 28, 2024, according to the notification issued by the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security on the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Pharmaceutical Catalog (2024)" (hereinafter referred to as the "National Medical Insurance Catalog"), the company's product Xidabenamine Tablets (Aipusha) has been newly included in the "National Medical Insurance Catalog" for the first time for the indication of Diffuse Large B-Cell Lymphoma, and Sigrectna Tablets (Shuangluoping) has successfully renewed its listing in the "National Medical Insurance Catalog".
Shenzhen Chipscreen Biosciences (688321.SH): The clinical trial application for Sidabonan has been accepted.
On November 27, Gelonghui reported that shenzhen chipscreen biosciences (688321.SH) announced that it recently received the "Acceptance Notice" for clinical trials of domestically produced pharmaceuticals issued by the National Medical Products Administration's Drug Evaluation Center, and the clinical trial application for chidamide has been accepted by the Drug Review Center of the National Medical Products Administration. Chidamide (brand name "Epidaza") is a national Class 1 innovative drug, uniquely discovered by the company as a new molecular entity with a novel mechanism. As the only orally available subtype-selective histone deacetylase (HDAC) inhibitor in the field, chidamide is effective against tumors.
No money again! Shenzhen Chipscreen Biosciences has "burned" 0.9 billion in R&D expenses over three years and plans to raise another 0.96 billion, nearly 30% of which will be used to supplement cash flow.
shenzhen chipscreen biosciences announced a plan for private placement, planning to raise 0.96 billion yuan, with 0.71 billion yuan for innovative drug research and development, and 0.25 billion yuan for supplementary working capital, reaching a replenishment ratio of 26.04%; Multiple research pipelines continue to burn money for shenzhen chipscreen biosciences, with a total research and development expense of 0.927 billion yuan from 2021 to 2023, currently 17 indication pipelines are in clinical trial stage.
Shenzhen Chipscreen Biosciences Seeks 960 Million Yuan From Share Issuance
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 30% Share Price Surge Not Quite Adding Up
